CompanyOverview|NASDAQ:RXRX] Recursion Pharmaceuticals' (NASDAQ: RXRX) stock price has seen a dramatic increase, not due to ...

Recursion CEO Chris Gibson defends the NIH, investing $1 million into a pre-seed venture to encourage critical research and ...

Plus: A shift in bird flu strategy, a new vaccine for meningococcal disease, a new AI genomics model from Nvidia and more.

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

Earlier this month, the Trump administration directed the National Institutes of Health (NIH) to impose limits on specific types of funding it provides to ...

The cuts hit the FDA’s medical device center particularly hard, impacting product reviewers and researchers of AI-enabled ...

Salt Lake City-based accelerator Altitude Lab is hoping it can entice biotechs impacted by the uncertainty surrounding federal grants.

Chris Gibson, Recursion’s head, cited the role small business grants played in helping his company grow its business.

If policymakers fail to act swiftly to restore medical research funding, then it’s up to those of us in the industry with the ...

Recursion Pharmaceuticals RXRX is expected to report its fourth-quarter 2024 results soon. The Zacks Consensus Estimate for ...

Danaher, Recursion Pharmaceuticals, Moderna, Thermo Fisher Scientific, AbbVie, Vertex Pharmaceuticals, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to ...